• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    2/13/24 4:52:09 PM ET
    $OTEC
    Blank Checks
    Finance
    Get the next $OTEC alert in real time by email
    425 1 g084031_8k.htm 8-K

       

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION 

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of

    the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): February 9, 2024

     

    OceanTech Acquisitions I Corp.

    (Exact name of registrant as specified in its charter)  

     

    Delaware   001-40450   85-2122558
    (State or other jurisdiction of
    incorporation or organization)
      (Commission
    File Number)
      (IRS Employer
    Identification No.)

     

    515 Madison Avenue, Suite 8133

    New York, New York 10022

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (929) 412-1272

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

      ☒ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
         
      ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
         
      ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
         
      ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of Each Class   Trading Symbol(s)   Name of Each Exchange
    on Which Registered
    Units, each consisting of one share of Class A Common Stock and one Redeemable Warrant   OTECU   The Nasdaq Stock Market LLC
    Class A Common Stock, $0.0001 par value per share   OTEC   The Nasdaq Stock Market LLC
    Redeemable Warrants, each exercisable for one share of Class A Common Stock at an exercise price of $11.50 per share   OTECW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     1

     

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    The stockholders (the “Stockholders”) of OceanTech Acquisitions I Corp., a Delaware corporation (“OTEC” or “OceanTech”) approved each of the proposals set forth below at the special meeting held on February 9, 2024 (the “Special Meeting”) following the notice provided by the definitive proxy/prospectus filed on January 2, 2024 as supplemented by the Form 8-K filed on January 19, 2024 (collectively, the “Proxy Statement”) with the Securities and Exchange Commission (“SEC”), as follows:

     

    ●Proposal One — The Business Combination Proposal. To approve and adopt the Agreement and Plan of Merger dated as of May 2, 2023, as amended by that certain Amendment No. 1 to Agreement and Plan of Merger, dated as of July 7, 2023 (collectively, the “Merger Agreement”), a copy of which is attached to the Proxy Statement as Annex A, and the transactions contemplated therein, including the business combination whereby R.B. Merger Sub Ltd., a company organized under the laws of the State of Israel and a wholly-owned subsidiary of OTEC will merge with and into Regentis Biomaterials Ltd., a company organized under the laws of Israel (“Regentis”), with Regentis surviving the merger as a wholly-owned subsidiary of OTEC (the “Business Combination”), and approve the transactions contemplated thereby, subject to the terms and conditions set forth in the Merger Agreement.

     

    ●Proposal Two — The Nasdaq Proposal. To approve, for purposes of complying with applicable Nasdaq listing rules, the issuance of more than 20% of the issued and outstanding OTEC common stock in connection with the Business Combination, including the issuance of the merger consideration, the converted options from the equity plan of Regentis, shares for OTEC’s sponsor’s contribution to OTEC’s trust account (the “Trust Account”) as part of each extension option, the earnout shares and the shares in the PIPE investment, and the resulting change in control in connection with the Business Combination.

     

    ●Proposal Three — The Restated OTEC Charter Proposal. To amend, immediately following and in connection with the closing of the Business Combination OTEC’s existing certificate of incorporation dated as of May 27, 2021, as amended on December 1, 2022 by that certain First Amendment to the Amended and Restated Certificate of Incorporation, as further amended on May 30, 2023 by that certain Second Amendment to the Amended and Restated Certificate of Incorporation, and as further amended on September 5, 2023 by that certain Amendment to the Amended and Restated Certificate of Incorporation and as may be further amended (collectively, the “Existing OTEC Charter”) to such proposed form set forth as Annex D to the Proxy Statement (the “Restated OTEC Charter”).

     

    ●Proposal Four – The Governance Proposals. To consider and vote upon, on a non-binding advisory basis, the following material differences between the Restated OTEC Charter and the Existing OTEC Charter as separate proposals in accordance with the SEC requirements:

     

    oProposal Four (a) – Changes to Authorized Capital Stock. To increase the total number of authorized shares of all classes of capital stock of OTEC from 111,000,000 shares consisting of (i) 100,000,000 shares of OTEC Class A Common Stock, (ii) 10,000,000 shares of OTEC Class B Common Stock and (iii) 1,000,000 shares of preferred stock, to 111,000,000 shares of the surviving company following the Business Combination (the “Post-Closing Company”) capital stock, consisting of (a) 110,000,000 shares of Post-Closing Company common stock and (b) 1,000,000 shares of preferred stock of the Post-Closing Company.

     

     2

     

     

    oProposal Four (b) – Increased Vote Required for Removal of Directors for Cause. To increase the vote required to remove directors of the Post-Closing Company for cause from a majority of the voting power to 66 2⁄3% of the voting power.

     

    oProposal Four (c) – Name Change. To change the name of OTEC from “OceanTech Acquisitions I Corp.” to “Regentis Biomaterials Corp.”.

     

    oProposal Four (d) – Removal of Blank Check Company Provisions. To eliminate various provisions applicable only to blank check companies, including business combination requirements.

     

    ●Proposal Five — The Equity Incentive Plan Proposal. To approve and adopt the current equity incentive plan, a copy of which is attached to the Proxy Statement as Annex C.

     

    ●Proposal Six — The Election of Directors Proposal. To elect, effective at the closing of the Business Combination, seven directors to serve staggered terms on the Post-Closing Company board of directors until the first, second and third annual meetings of stockholders following such closing, as applicable, and until their respective successors are duly elected and qualified.

     

    oClass I (to serve until 2024 annual meeting): Surendra Ajjarapu, Susan Alpert, Pini Ben Elazar

     

    oClass II (to serve until 2025 annual meeting): Efraim Cohen-Arazi, Keith Valentine

     

    oClass III (to serve until 2026 annual meeting): Ehud Geller, Jeff Dykan

     

    ●Proposal Seven — The Adjournment Proposal. To adjourn the special meeting to a later date or dates, if necessary, if the parties are not able to consummate the Business Combination.

     

    On the record date of December 29, 2023, OTEC had 3,497,475 shares entitled to vote at the Special Meeting, and 2,968,524 shares were present in person or by proxy, representing a quorum. At the Special Meeting, the Stockholders voted on each proposal presented, as described in the Proxy Statement, and cast their votes as described below: 

     

    The Stockholders approved each proposal. The following is a tabulation of the voting results:

     

    Proposal 1: The Business Combination Proposal 

    FOR AGAINST ABSTAIN
    2,965,975 2,549 0

     

    Proposal 2: Nasdaq Proposal 

    FOR AGAINST ABSTAIN
    2,965,975 2,549 0

     

    Proposal 3: The Restated OTEC Charter Proposal

    FOR AGAINST ABSTAIN
    2,965,975 2,549 0

     

     3

     

     

    Proposal 4: The Governance Proposals 

     

    Proposal 4 (a): Changes to Authorized Capital Stock 

    FOR AGAINST ABSTAIN
    2,895,975 2,549 70,000

     

    Proposal 4 (b): Increased Vote Required for Removal of Directors for Cause 

    FOR AGAINST ABSTAIN
    2,895,975 2,549 70,000

     

    Proposal 4 (c): Name Change 

    FOR AGAINST ABSTAIN
    2,965,975 2,549 0

     

    Proposal 4 (d): Removal of Blank Check Company Provisions 

    FOR AGAINST ABSTAIN
    2,965,975 2,549 0

     

    Proposal 5: The Equity Incentive Plan Proposal 

    FOR AGAINST ABSTAIN
    2,895,757 2,767 70,000

     

    Proposal 6: The Election of Directors Proposal

     

    Surendra Ajjarapu 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Susan Alpert 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Pini Ben Elazar 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Efraim Cohen-Arazi 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Keith Valentine 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Ehud Geller 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

    Jeff Dykan 

    FOR AGAINST ABSTAIN
    2,895,975 0 72,549

     

     4

     

     

    Accordingly, such proposals, having received the votes required by applicable law, were declared to be duly adopted by the Stockholders, and a vote for the proposal to authorize adjournment of the Special Meeting was unnecessary. No other items were presented for stockholder approval at the Special Meeting.

     

    In connection with the Special Meeting, Stockholders holding 800,312 shares of OTEC class A common stock (the “Public Shares”) exercised their right to redeem their shares for a pro rata portion of the funds in the Trust Account. The trustee of the Trust Account is calculating the final amount of the funds to be removed from the Trust Account in connection with such redemptions, but the current preliminary calculations are that approximately $9,227,597.36 (approximately $11.53 per Public Share)  will be removed from the Trust Account to pay such holders. OTEC will amend this Form 8-K (or file a new Form 8-K) should the actual amounts materially differ from the foregoing estimated amounts. 

     

     5

     

     

    Cautionary Statement Regarding Forward-Looking Statements

     

    This Filing is provided for informational purposes only and has been prepared to assist interested parties in making their own evaluation with respect to the Business Combination and for no other purpose. No representations or warranties, express or implied are given in, or in respect of, this Filing. To the fullest extent permitted by law under no circumstances will Regentis, OceanTech, Merger Sub, Sponsor or any of their respective subsidiaries, interest holders, affiliates, representatives, partners, directors, officers, employees, advisors or agents be responsible or liable for any direct, indirect or consequential loss or loss of profit arising from the use of this Filing, its contents, its omissions, reliance on the information contained within it, or on opinions communicated in relation thereto or otherwise arising in connection therewith. This Filing does not purport to be all-inclusive or to contain all the information that may be required to make a full analysis of OceanTech, Regentis or the Business Combination. Readers of this Filing should each make their own evaluation of OceanTech and Regentis and of the relevance and adequacy of the information and should make such other investigations as they deem necessary. This Filing contains certain “forward-looking statements” within the meaning of the federal securities laws, including statements regarding the completion of the Business Combination and the expected listing on Nasdaq, and OceanTech’s and Regentis’ expectations, plans or forecasts of future events and views as of the date of this Filing. OceanTech and Regentis anticipate that subsequent events and developments will cause OceanTech’s and Regentis’ assessments to change. These forward-looking statements, which may include, without limitation, words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will”, “could,” “should,” “believes,” “predicts,” “potential,” “might,” “continues,” “think,” “strategy,” “future,” and similar expressions, involve significant risks and uncertainties (most of which factors are outside of the control of OceanTech or Regentis). Factors that may cause such differences include but are not limited to: (1) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement; (2) the risk that the Business Combination may not be completed in a timely manner or at all, which may adversely affect the price of the securities; (3) the risk that the Business Combination may not be completed by OceanTech’s business combination deadline; (4) the inability to complete the Business Combination, including but not limited to due to the failure to obtain approval of the stockholders of OceanTech or Regentis for the Merger Agreement, to satisfy the minimum net tangible assets and minimum cash at closing requirements, to receive certain governmental, regulatory and third party approvals or to satisfy other conditions to closing in the Merger Agreement; (5) the failure to achieve the minimum amount of cash available following any redemptions by OceanTech’s stockholders; (6) the inability to obtain or maintain the listing of OceanTech’s common stock on Nasdaq following the Business Combination, including but not limited to redemptions exceeding anticipated levels or the failure to meet Nasdaq’s initial listing standards in connection with the consummation of the Business Combination; (7) the effect of the announcement or pendency of the Business Combination on Regentis’ business relationships, operating results, and business generally; (8) risks that the Business Combination disrupts current plans and operations of Regentis; (9) the inability to realize the anticipated benefits of the Business Combination and to realize estimated pro forma results and underlying assumptions, including but not limited to with respect to estimated stockholder redemptions and costs related to the Business Combination; (10) the possibility that OceanTech or Regentis may be adversely affected by other economic or business factors; (11) changes in the markets in which Regentis competes, including but not limited to with respect to its competitive landscape, technology evolution, or regulatory changes; (12) changes in domestic and global general economic conditions; (13) risk that Regentis may not be able to execute its growth strategies; (14) the risk that Regentis experiences difficulties in managing its growth and expanding operations after the Business Combination; (15) the risk that the parties will need to raise additional capital to execute the business plan, which may not be available on acceptable terms or at all; (16) the ability to recognize the anticipated benefits of the Business Combination to achieve its commercialization and development plans, and identify and realize additional opportunities, which may be affected by, among other things, competition, the ability of Regentis to grow and manage growth economically and hire and retain key employees; (17) risk that Regentis may not be able to develop and maintain effective internal controls; (18) the risk that Regentis may fail to keep pace with rapid technological developments to provide new and innovative products and services, or may make substantial investments in unsuccessful new products and services; (19) the ability to develop, license or acquire new products and services; (20) the risk that Regentis is unable to secure or protect its intellectual property; (21) the risk of product liability or regulatory lawsuits or proceedings relating to Regentis’ business; (22) the risk of cyber security or foreign exchange losses; (23) changes in applicable laws or regulations; (24) the outcome of any legal proceedings that may be instituted against the parties related to the Merger Agreement or the Business Combination; (25) the impact of the global COVID-19 pandemic and response on any of the foregoing risks, including but not limited to supply chain disruptions; and (26) other risks and uncertainties identified in the Form S-4, including those under “Risk Factors” therein, and in other filings with the SEC made by OceanTech. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of OceanTech’s Form S-4 and definitive proxy statement, Annual Report on Form 10-K, and Quarterly Reports on Form 10-Q filed with the SEC with respect to the Business Combination, and other documents filed by OceanTech from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. The foregoing list of factors is not exhaustive, are provided for illustrative purposes only, and are not intended to serve as, and must not be relied on as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Forward-looking statements speak only as of the date they are made. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that neither OceanTech nor Regentis presently know or that OceanTech and Regentis currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. OceanTech and Regentis anticipate that subsequent events and developments will cause OceanTech’s and Regentis’ assessments to change. However, while OceanTech and Regentis may elect to update these forward-looking statements at some point in the future, OceanTech and Regentis specifically disclaim any obligation to do so. Neither OceanTech nor Regentis gives any assurance that OceanTech or Regentis, or the combined company, will achieve its expectations. Accordingly, undue reliance should not be placed upon the forward-looking statements, and they should not be relied upon as representing OceanTech’s and Regentis’ assessments as of any date subsequent to the date of this Filing.

     

     6

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, OTEC has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

    OCEANTECH ACQUISITIONS I CORP.

         
    Date: February 13, 2024 By: /s/ Suren Ajjarapu
        Name: Suren Ajjarapu
        Title: Chief Executive Officer
        (Principal Executive Officer)

     

     7

    Get the next $OTEC alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OTEC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OTEC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OceanTech Acquisitions I Corp. Announces Redemption of Shares

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company

    6/7/23 9:29:00 AM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. Announces Postponement of Special Meeting of Stockholders Until May 30, 2023 at 11:30 a.m. EDT

    OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is

    5/25/23 11:09:00 PM ET
    $OTEC
    Blank Checks
    Finance

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    SEC Filings

    View All

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 4:52:09 PM ET
    $OTEC
    Blank Checks
    Finance

    OceanTech Acquisitions I Corp. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)

    2/13/24 4:50:55 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 425 filed by OceanTech Acquisitions I Corp.

    425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/30/24 4:06:26 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Owl Creek Asset Management, L.P.

    4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    6/1/23 9:18:13 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Aspire Acquistion Llc

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/25/23 1:02:27 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form 3 filed by new insider Fell Donald G.

    3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)

    4/21/23 6:27:45 PM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Financials

    Live finance-specific insights

    View All

    Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.

    Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac

    5/3/23 7:45:00 AM ET
    $OTEC
    Blank Checks
    Finance

    $OTEC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/13/24 5:54:33 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    2/5/24 2:07:43 PM ET
    $OTEC
    Blank Checks
    Finance

    SEC Form SC 13G/A filed by OceanTech Acquisitions I Corp. (Amendment)

    SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)

    1/10/24 11:01:25 AM ET
    $OTEC
    Blank Checks
    Finance